BioSyent (CVE:RX) Stock Passes Below 50-Day Moving Average of $7.99

Shares of BioSyent Inc. (CVE:RXGet Rating) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$7.99 and traded as low as C$7.96. BioSyent shares last traded at C$8.00, with a volume of 2,500 shares changing hands.

BioSyent Trading Up 0.5 %

The stock has a market cap of C$99.26 million and a PE ratio of 16.67. The company has a debt-to-equity ratio of 4.74, a quick ratio of 7.23 and a current ratio of 8.09. The company’s 50-day moving average price is C$7.99 and its 200 day moving average price is C$8.42.

BioSyent (CVE:RXGet Rating) last announced its earnings results on Wednesday, May 18th. The company reported C$0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C$0.11 by C$0.02. The firm had revenue of C$7.04 million during the quarter, compared to analysts’ expectations of C$7.00 million. On average, sell-side analysts forecast that BioSyent Inc. will post 0.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other BioSyent news, insider Blair Driscoll purchased 25,000 shares of the company’s stock in a transaction on Thursday, June 30th. The stock was acquired at an average price of C$7.79 per share, for a total transaction of C$194,750.00. Following the completion of the purchase, the insider now directly owns 2,146,100 shares in the company, valued at approximately C$16,718,119.

About BioSyent

(Get Rating)

BioSyent Inc, a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with's FREE daily email newsletter.